Armis Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$238K Buy
1,575
+47
+3% +$7.42K 0.02% 431
2026
Q2
$246K Buy
+1,528
New +$207K 0.02% 411

Other funds holding XBI

Armis Advisers's XBI Position: Q3 2026 in Review

Armis Advisers increased its State Street SPDR S&P Biotech ETF (XBI) stake by 3.1% in Q3 2026, buying an estimated $7.42K and bringing the position to 1,575 shares worth $238K. The position accounts for 0.02% of the portfolio, ranked #431.

Armis Advisers first reported a position in XBI in Q2 2026 and has held it in 2 quarters since. The position peaked at $246K in Q2 2026. 964 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Armis Advisers held 1,575 shares of State Street SPDR S&P Biotech ETF worth $238K as of Q3 2026.
  • Armis Advisers bought 47 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $7.42K.
  • State Street SPDR S&P Biotech ETF made up 0.02% of Armis Advisers's portfolio in Q3 2026, its #431 holding.
  • Armis Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q2 2026 and has held it in 2 quarters since.
  • Armis Advisers's State Street SPDR S&P Biotech ETF position peaked at $246K in Q2 2026.
  • 964 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Armis Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.